#ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other pointers? A cohort study in Turkey showed to consider FMF in pts with red mono-oligo arthritis in lower limbs & spondyloarthropathy. 20% were colchicine resistant @RheumNow https://t.co/JXGcgCrhPu

#ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A case-control study in Turkey reported 16% of unindicated appendectomies prior to FMF diagnosis. This group had late diagnosis and associated with M694V homozygous mutation @RheumNow https://t.co/QtxjuHDXYC

FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s

Mihai et al. Immunosuppressive treatment in SSc assoc lower GI symptom score. @RheumNow #ACR22 Abstr#2174 https://t.co/Y1gyRe8ron https://t.co/tz9cIESzqo

Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw

Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patients. Initial treatment response, age and Numanotype V arterial involvement predictors. @RheumNow #ACR22 Abstr#L017 https://t.co/5t00prCtFT https://t.co/GGUUNQqyoL

Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54

I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow

Promises to be a fantastic session! 🌟Delighted PMR is getting the attention it deserves 🌟 2pm GMT/ 9am EST #ACR22 @RheumNow @SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO

Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ